BioCardia Reports Published Study Showing Helix Biotherapeutic Delivery System Used in CardiAMP Phase III Heart Failure Trial Has Fewest Adverse Events Among Competitive Delivery SystemsGlobeNewsWire • 12/01/20
BioCardia Reports Third Quarter 2020 Financial Results and Business HighlightsGlobeNewsWire • 11/10/20
Published Peer-reviewed Initial Data from BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Demonstrates Improvement in Heart Failure Patients Measured by Exercise Outcomes and Cardiac FunctionGlobeNewsWire • 10/26/20
BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy Through Wrist ArteryGlobeNewsWire • 09/29/20
BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020GlobeNewsWire • 08/26/20
BioCardia Reports Second Quarter 2020 Financial Results and Business HighlightsGlobeNewsWire • 08/13/20
BioCardia, Inc. (BCDA) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/12/20
BioCardia To Conduct Mid-Year Conference Call and Corporate Update August 13, 2020GlobeNewsWire • 08/07/20
BioCardia Announces Activation of Pivotal Trial Studying CardiAMP Cell Therapy Trial to Treat Chronic Myocardial IschemiaGlobeNewsWire • 07/01/20
BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 EraGlobeNewsWire • 06/29/20
BioCardia Reports First Quarter 2020 Financial Results and Business HighlightsGlobeNewsWire • 05/15/20
Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing ApprovalGlobeNewsWire • 04/30/20
BioCardia Awarded New U.S. Patent Covering Helix System for Local Biotherapeutic Delivery of Autologous and Allogenic Cells to the HeartGlobeNewsWire • 04/28/20